Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Harvard Bioscience, Inc. before investing.

In this article, we go over a few key elements for understanding Harvard Bioscience, Inc.’s stock price such as:

• Harvard Bioscience, Inc.’s current stock price and volume
• Why Harvard Bioscience, Inc.’s stock price changed recently
• Upgrades and downgrades for HBIO from analysts
• HBIO’s stock price momentum as measured by its relative strength

About Harvard Bioscience, Inc. (HBIO)

Before we jump into Harvard Bioscience, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Harvard Bioscience, Inc. is a developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. It has organized its product line activities into two product families, cellular and molecular technology (CMT) and Preclinical. Its CMT product family is composed of products supporting research related to molecular, cellular organ and organoid technologies, with additional application in the field of bio-production of pharmaceuticals and therapeutics. Its preclinical product family includes four business lines that support the preclinical research and testing phase for drug development, and in particular testing related to data collection and analysis for safety and regulatory compliance. Its brands include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs and others.

Want to learn more about Harvard Bioscience, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Harvard Bioscience, Inc..

Harvard Bioscience, Inc.’s Stock Price as of Market Close

As of December 21, 2023, 4:00 PM, CST, Harvard Bioscience, Inc.’s stock price was $5.28.

Harvard Bioscience, Inc. is up 5.6% from its previous closing price of $5.00.

During the last market session, Harvard Bioscience, Inc.’s stock traded between $4.91 and $5.13. Currently, there are 42.69 million shares of Harvard Bioscience, Inc. stock available for purchase.

Unfortunately, Harvard Bioscience, Inc.’s P/E ratio is not significant enough to use for stock price evaluation. We recommend investors evaluate other financial metrics to understand its overall valuation.

Harvard Bioscience, Inc. Stock Price History

Harvard Bioscience, Inc.’s (HBIO) price is currently up 23.94% so far this month.

During the month of December, Harvard Bioscience, Inc.’s stock price has reached a high of $5.30 and a low of $4.23.

Over the last year, Harvard Bioscience, Inc. has hit prices as high as $6.29 and as low as $1.98. Year to date, Harvard Bioscience, Inc.’s stock is down 25.11%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Harvard Bioscience, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of December 20, 2023, there was 1 analyst who downgraded Harvard Bioscience, Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Harvard Bioscience, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Harvard Bioscience, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Harvard Bioscience, Inc.’s current valuation based on AAII’s Value Grade is a D, which means it is considered to be Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Harvard Bioscience, Inc. (HBIO) by visiting AAII Stock Evaluator.

Relative Price Strength of Harvard Bioscience, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of December 20, 2023, Harvard Bioscience, Inc. has a weighted four-quarter relative price strength of 21.89%, which translates to a Momentum Score of 94 and is considered to be Very Strong.

Want to learn more about how Harvard Bioscience, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Harvard Bioscience, Inc. Stock Price: Bottom Line

As of December 21, 2023, Harvard Bioscience, Inc.’s stock price is $5.28, which is up 5.6% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Harvard Bioscience, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.